Reversible Contraceptive Potential of FDA Approved Excipient N, N-Dimethylacetamide in Male Rats
Development of an effective male contraceptive agent remains a challenge. The present study evaluates the potential of N, N-Dimethylacetamide (DMA), a FDA approved excipient as a male contraceptive agent. Male Sprague Dawley rats injected with DMA for a period of 8 weeks (one injection per week) sho...
Main Authors: | Nupur Khera, Chafik Ghayor, Anna K. Lindholm, Ekaterina Pavlova, Nina Atanassova, Franz E. Weber |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2020.601084/full |
Similar Items
-
Bromodomain Protein Inhibition Protects β-Cells from Cytokine-Induced Death and Dysfunction via Antagonism of NF-κB Pathway
by: Vinny Negi, et al.
Published: (2024-06-01) -
Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
by: Adam P. Cribbs, et al.
Published: (2021-02-01) -
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
by: Kenneth K. W. To, et al.
Published: (2023-03-01) -
N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
by: Joshua A. Nord, et al.
Published: (2022-09-01) -
Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer
by: Krishan Kumar, et al.
Published: (2023-05-01)